| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Glycodeoxycholic acid-d6 does not have a specific pharmacological target as it is a stable isotope-labeled tracer. Glycodeoxycholic acid itself is a bile acid involved in lipid digestion and absorption. Its "target" in research is the study of bile acid metabolism, particularly in conditions such as cholestatic liver diseases.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro activity of Glycodeoxycholic acid-d6 is measured as its utility as a tracer in metabolic studies. In cell culture and cell-free systems, the labeled bile acid is used to study bile acid transport, metabolism, and signaling. Its "activity" is reflected in its metabolic incorporation and its ability to serve as a probe for studying bile acid pathways. |
| ln Vivo |
In vivo, Glycodeoxycholic acid-d6 is used to study bile acid metabolism, enterohepatic circulation, and lipid digestion. Administered orally or intravenously, the labeled bile acid is absorbed, distributed to the liver and intestine, and recycled through the enterohepatic circulation. These studies provide quantitative data on bile acid kinetics and metabolism.
|
| Enzyme Assay |
In vitro enzyme assays with Glycodeoxycholic acid-d6 typically involve studying enzymes of bile acid metabolism such as bile acid-CoA ligase or bile acid amidases. The labeled substrate is incubated with enzyme preparations, and the reaction products are analyzed by mass spectrometry. These assays provide mechanistic insights into bile acid conjugation and metabolism.
|
| Cell Assay |
In vitro cell culture experiments with Glycodeoxycholic acid-d6 involve treating hepatocytes or intestinal cells with the labeled bile acid. Cells are cultured to allow uptake and metabolism of the compound. Following incubation, cells and media are collected, and bile acids are extracted for analysis by mass spectrometry to study bile acid transport and metabolism.
|
| Animal Protocol |
In vivo animal experiments with Glycodeoxycholic acid-d6 typically involve administering the labeled compound via oral gavage or injection to rodents. Blood, bile, liver, and intestinal contents are collected at various time points. Isotopic enrichment of glycodeoxycholic acid and its metabolites is measured by mass spectrometry. These studies provide quantitative data on bile acid metabolism and enterohepatic circulation.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of Glycodeoxycholic acid-d6 are essentially identical to those of natural glycodeoxycholic acid. As a bile acid, it is absorbed in the intestine, taken up by the liver, conjugated, and secreted into bile, undergoing enterohepatic circulation. The deuterium label allows for precise tracking of its metabolism.
|
| Toxicity/Toxicokinetics |
Glycodeoxycholic acid-d6 has a low toxicity profile as a naturally occurring bile acid. The deuterium label does not introduce additional toxicity. For research use, standard laboratory safety practices are sufficient. It is not considered a hazardous substance.
|
| References | |
| Additional Infomation |
Glycodeoxycholic acid-d6 is a deuterium-labeled form of glycodeoxycholic acid, a bile acid crucial for lipid digestion and absorption. It is used as a tracer in studies of bile acid metabolism, such as cholestatic liver diseases. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only.
|
| Molecular Formula |
C26H37D6NO5
|
|---|---|
| Molecular Weight |
455.66
|
| Exact Mass |
455.351
|
| CAS # |
2483831-98-5
|
| Related CAS # |
Glycodeoxycholic Acid;360-65-6
|
| PubChem CID |
162642794
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
727
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1([C@H](O)C(C[C@@]2(C)[C@@]1(CC[C@]1([H])[C@]2([H])C([2H])([C@H](O)[C@@]2([C@@]([H])([C@@H](CCC(NCC(O)=O)=O)C)CC[C@]21[H])C)[2H])[H])([2H])[2H])([2H])[2H]
|
| InChi Key |
WVULKSPCQVQLCU-VXQFIXJESA-N
|
| InChi Code |
InChI=1S/C26H43NO5/c1-15(4-9-23(30)27-14-24(31)32)19-7-8-20-18-6-5-16-12-17(28)10-11-25(16,2)21(18)13-22(29)26(19,20)3/h15-22,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16-,17-,18+,19-,20+,21+,22+,25+,26-/m1/s1/i10D2,12D2,13D2
|
| Chemical Name |
2-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-2,2,4,4,11,11-hexadeuterio-3,12-dihydroxy-10,13-dimethyl-1,3,5,6,7,8,9,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1946 mL | 10.9731 mL | 21.9462 mL | |
| 5 mM | 0.4389 mL | 2.1946 mL | 4.3892 mL | |
| 10 mM | 0.2195 mL | 1.0973 mL | 2.1946 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
